PCSK9 Forum
Click here to forward this email to a colleague
Facebook Twitter RSS YouTube linkedin
Home  |  About  |  PCSK9  |  News  |  Commentary  |  Trials  |  Videos  |  Resources  |  Contact

What will be hot at ACC.2018?

All eyes will be on ODYSSEY OUTCOMES, the first of the Late-Breaking Clinical Trials at the Annual Scientific Sessions of the American College of Cardiology this March.

This is the second completed cardiovascular outcomes study with a PCSK9 inhibitor. In contrast to FOURIER, ODYSSEY OUTCOMES has studied post-acute coronary syndrome patients rather than those with stable cardiovascular disease.

Gregory G. Schwartz (VA Medical Center and University of Colorado School of Medicine, Denver, USA) discusses the prospects for PCSK9 inhibition in ACS patients.

Watch the webcast »

Check back for the latest news and views about PCSK9 science and translation to the clinic
Like us on Facebook
For the latest updates, PCSK9 news and analysis.
Follow us on Twitter
Hot topics, news and conference reports.
YouTube Channel
For videos, interviews and webcasts from leading experts.
Our popular therapeutic guide

Read online & download second edition now »

Register now at www.pcsk9forum.org to receive the updated third edition e-book with post ACC18 content.
New eBook
Questions & Answers

Why are new treatments needed?

Read the full answer and other questions on the PCSK9 Forum »
Educational Partners
and Supporters
Amgen The Medicines Company Sanofi
Copyright PCSK9 Forum 2018. Please click here to unsubscribe from future mailings.